Individual Risk Profiles for Adverse Drug Reactions in Geriatric Patients

N/ANot Yet RecruitingNCT05247814

RWTH Aachen University2,000 enrolled

Overview

This project will generate a prospective cohort of geriatric patients with polypharmacy which will be characterized for vulnerability profiles of adverse drug reactions.

Adverse drug reactions are common in older patients and can lead to severe outcomes such as falls, hospitalizations and death. They are dose-dependent and may for example be caused by inappropriate dosing due to a reduced kidney function. Also, the use of potentially inappropriate medications in older patients can result in a negative benefit-/ risk-ratio. Additionally, drug metabolism in older patients is altered due to a variety of reasons and pharmacogenetic variants of drug metabolizing enzymes can lead to a more than 10-fold interinidividual variation of drug clearance. The risk of the individual patient to experience an adverse drug reactions is determined by many reasons. Therefore, this study aims to identify patient risk profiles with regard to pharmacogenetics, drug interactions, impaired functional and cognitive status and individual drug metabolism. Participants for this study will be consecutively recruited from patients admitted to the Interdisciplinary Polypharmacy Consultation Service of the Department of Geriatric's University Outpatient Clinic in cooperation with the Institute of Clinical Pharmacology. Regardless of their participation in this study, patients in the outpatient clinic will perform several tests and questionnaires following the comprehensive geriatric assessment. The purpose of the cohort study is to document and evaluate routine health data collected in the outpatient clinic for polypharmacy in geriatric patients (laboratory tests as well as a comprehensive medication history with therapy recommendations issued by a subsequent pharmaceutical council for both the patients and the primary care physicians). Procedures conducted specifically for this study are a long-term capture and detailed history of all suspected adverse drug reactions, examining the fear of falling (FES-I questionnaire) and blood sampling for exploratory pharmacogenomic analyses (on cohort level, not patient diagnostics). Aim of the long-term cohort of geriatric patients with polypharmacy is to identify risk profiles for adverse drug reactions that are specific for the population of older individuals.

Study Type

OBSERVATIONAL

Enrollment

2,000

Conditions

Polypharmacy Pharmacogenetics Pharmacogenomic Testing Drug-Related Side Effects and Adverse Reactions

Interventions

Pharmacogenomic testing of a panel of important pharmacogenes to detect genetic variants and evaluate the association between genetically predicted and measured drug metabolismGENETIC

All planned interventions are explorative analyses of biological and genetic risk profiles that can contribute to patients' individual risk for adverse drug reactions, i.e. due to variability in drug metabolism

Adverse Drug Reaction detectionOTHER

During appointments in the university outpatient clinic, patients will undergo a comprehensive adverse drug reaction (ADR) assessment based on an ADR diary they were handed at enrolment

Falls Efficacy Scale International (FES-I)

Eligibility

Sex: ALLMin age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 70 years or older * Current drug therapy with three or more drugs * Being a patient in the interdisciplinary polypharmacy consultation service of the geriatric university outpatient clinic * Sufficient mobility (minimum: Wheelchair mobility) * Written informed consent of the patient or the legal representative Exclusion Criteria: * No sufficient communication possible * Patients classified as terminally ill by the medical staff * Patients, that are incapable to give their informed consent and who do not have a legal representative

Outcomes

Primary Outcomes

Identification of vulnerability profiles of adverse drug reactions

To investigate patient-specific risk profiles for adverse drug reactions, the focus of this study is on analizing patients' functional and cognitive status, pharmacogenetics, and individual metabolic capacity (phenotype/genotype relationship).

Time frame: February 2022 - February 2032

Central Contacts

Mathias Freitag

CONTACT

+492417501116 mfreitag@ukaachen.de

Julia C. Stingl, MD, ScD

CONTACT

+492418089130 jstingl@ukaachen.de

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.